This study focuses on individuals with Triple-negative breast cancer, which is a type of breast cancer that lacks certain common receptors typically used to guide treatment. The research is specifically looking at patients whose cancer has returned in the same area and cannot be removed by surgery, or has spread to other parts of the body, and who are not candidates for certain other therapies due to the absence of a specific protein called PD-L1. The purpose of the study is to compare the effectiveness of a new medication called BNT327 combined with chemotherapy against a combination of chemotherapy and a placebo.

The treatment involves several different medications used as chemotherapy, which are drugs designed to kill fast-growing cancer cells. These drugs include paclitaxel, gemcitabine, carboplatin, and eribulin. Participants will receive these medications through an intravenous infusion, a process where medicine is delivered directly into a vein. Some participants will receive BNT327 along with the drugs, while others will receive the placebo along with the drugs. This is a double-blind study, meaning neither the participants nor the researchers know which specific treatment is being administered during the course of the trial.

During the study, researchers will monitor how long patients live and how long they remain stable without the cancer growing further. The study also tracks how well the tumors shrink or disappear in response to the medicine. Changes in the patient’s overall health and how they feel physically will also be observed to ensure the safety of the treatments provided.